Fmr LLC Purchases New Holdings in Amneal Pharmaceuticals Inc (AMRX)

Fmr LLC purchased a new stake in Amneal Pharmaceuticals Inc (NYSE:AMRX) during the second quarter, according to its most recent filing with the SEC. The firm purchased 7,943,403 shares of the company’s stock, valued at approximately $130,351,000. Fmr LLC owned 2.66% of Amneal Pharmaceuticals at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Fosun International Ltd acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $333,013,000. BlackRock Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $95,312,000. TPG Group Holdings SBS Advisors Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $67,438,000. TCW Group Inc. acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $42,390,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth $38,076,000. Institutional investors and hedge funds own 31.84% of the company’s stock.

A number of analysts have recently weighed in on AMRX shares. Morgan Stanley started coverage on Amneal Pharmaceuticals in a research report on Monday, July 23rd. They issued an “overweight” rating and a $22.00 price objective for the company. Canaccord Genuity reaffirmed a “hold” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a research report on Tuesday, September 4th. SunTrust Banks cut Amneal Pharmaceuticals from a “buy” rating to a “hold” rating and set a $15.00 price target for the company. in a research report on Tuesday, October 16th. ValuEngine cut Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 27th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price target on shares of Amneal Pharmaceuticals in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $22.75.

Shares of AMRX opened at $19.09 on Wednesday. Amneal Pharmaceuticals Inc has a one year low of $13.47 and a one year high of $24.48. The company has a quick ratio of 1.25, a current ratio of 2.01 and a debt-to-equity ratio of 2.85. The stock has a market cap of $5.66 billion, a price-to-earnings ratio of 30.30, a PEG ratio of 0.90 and a beta of 1.56.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings results on Thursday, August 9th. The company reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.01. Amneal Pharmaceuticals had a negative return on equity of 8.74% and a negative net margin of 52.94%. The company had revenue of $462.33 million during the quarter, compared to analysts’ expectations of $460.82 million. The business’s quarterly revenue was down 2.5% on a year-over-year basis. As a group, equities research analysts expect that Amneal Pharmaceuticals Inc will post 0.94 earnings per share for the current year.

In other news, CFO Bryan M. Reasons sold 11,698 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total value of $276,657.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nikita Shah sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total value of $1,173,000.00. The disclosure for this sale can be found here. Insiders own 3.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Fmr LLC Purchases New Holdings in Amneal Pharmaceuticals Inc (AMRX)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/07/fmr-llc-purchases-new-holdings-in-amneal-pharmaceuticals-inc-amrx.html.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Further Reading: What is a conference call?

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals Inc (NYSE:AMRX).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply